Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Bausch Health Companies Inc (NY: BHC )

7.950 -0.020 (-0.25%)
Official Closing Price Updated: 7:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch Health Companies Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Jim Cramer's Top Stocks For 2022: Eli Lilly, Honeywell And More
Jim Cramer announced his top stock picks for 2022 Wednesday on CNBC's "Fast Money Halftime Report." The fo... 
Via Benzinga
Stock Market Crash Coming? 7 Wall Street Pros Make Their Predictions
December is when analysts and banks issue their extensive stock market outlook and winning stocks for the new year. 
Via InvestorPlace
BHC Stock: 9 Things to Know as Jim Cramer Buys Bausch Health
The Mad Money host announced a new position in Bausch Health amid the spread of the omicron variant. Here's what you should know. 
Via InvestorPlace
4 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t... 
Via Benzinga
Unusual Options Activity Insight: Bausch Health Companies
Bausch Health Companies (NYSE:BHC) shares experienced unusual... 
Via Benzinga
Unusual Options Activity Insight: Bausch Health Companies
Bausch Health Companies (NYSE:BHC) shares experienced unusua... 
Via Benzinga
Why Did Bausch Health Shares Plunge Today?
Bausch Health Companies Inc (NYSE: BHC) reported Q3 revenues of $2.111 billion, down 1% Y/Y, missing the consensus of $2.66 billion. Excluding the impact of foreign... 
Via Benzinga
Bausch Health Companies inc (BHC) Q3 2021 Earnings Call Transcript
BHC earnings call for the period ending October 2, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Committee Recommends Approval Of Merck, Pfizer's Pneumococcal Vaccine... 
Via Benzinga
Exposures Product Safety
Friday Market Coverage
New hiring again failed to rise in Sept., the 2nd month in a row which may be good news because it could delay the Fed tapering. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
Why Bausch Health Companies Stock Zoomed 8% Higher Today
One analyst crunches the numbers to come up with a share price valuation well above current levels. 
Via The Motley Fool
NYSE: BHC Shareholder Notice: Investigation over Potential Wrongdoing at Bausch Health Companies Inc.
San Diego, CA -- (SBWIRE) -- 09/13/2021 -- An investigation on behalf of investors in Bausch Health Companies Inc. (NYSE: BHC) shares over potential wrongdoing at Bausch Health Companies Inc. was... 
Via SBWire
Topics Supply Chain
Exposures COVID-19 Supply Chain
Bausch Pays $300M For Diabetes Drug Lawsuit: Reuters
Reuters reports that Bausch Health Companies Inc (NYSE: BHC) will pay $300 million to settle an antitrust lawsuit related to illegally maintaining a monopoly on... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Bausch Health Companies Inc. (NYSE:BHC) Investor Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 08/16/2021 -- Bausch Health Companies Inc is under investigation over potential securities laws in connection with certain financial statements. 
Via SBWire
Topics Supply Chain
Exposures COVID-19 Supply Chain
Why Bausch Health Companies Is Plunging Today
The turnaround isn't happening as fast as investors expected. 
Via The Motley Fool
Topics Product Recall
Exposures Legal Product Safety
Q2 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios
The latest round of 13F filings from institutional investors is out, revealing to the world the stocks that some of the richest and most successful investors have been buying and... 
Via Benzinga
75 Biggest Movers From Yesterday
Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares climbed 68.1% to close at $58.25 on Tuesday after the company announced that the it has received approval for a... 
Via Benzinga
Bausch Health Companies inc (BHC) Q2 2021 Earnings Call Transcript
BHC earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
48 Stocks Moving In Tuesday's Mid-Day Session
Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 64.4% to $7.15 after a Form 4 filing from the company showed 10% shareholder Retail Ecommerce Ventures... 
Via Benzinga
Bausch Health Misses On Q2 Sales, Cuts FY21 Outlook, Plans IPO For Medical Aesthetics Business
Bausch Health Companies Inc (NYSE: BHC) has reported Q2 revenues of $2.1 billion, +26% Y/Y, and missing the consensus of $2.12 billion. Revenue increased organically by... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Earnings Outlook For Bausch Health Companies
Bausch Health Companies (NYSE:BHC) releases its next round of earnings this Tuesday, August 03. Here is Benzinga's essential guide to Bausch Health Companies's Q2 earnings report... 
Via Benzinga
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Unusual Options Activity Insight: Bausch Health Companies
Shares of Bausch Health Companies (NYSE:BHC) saw some unusual options activity on Wednesday. Following the unusual option alert, the stock price moved up to $28.94. Sentiment:... 
Via Benzinga
Analyzing Bausch Health Companies's Unusual Options Activity
On Thursday, shares of Bausch Health Companies (NYSE:BHC) saw unusual options activity. After the option alert, the stock price moved down to $28.52. Sentiment: BEARISH Option... 
Via Benzinga
New Month And Half Year
Welcome to H2. In theory, if markets did well in H1 they tend to close the year up. 
Via Talk Markets
Reconsidered Boom
The US markets tried to repeat the big rise from yesterday, and appears to have succeeded. 
Via Talk Markets
Charles River's Jim Foster Beat The Trauma Of Being CEO
Think taking over the family business is easy? Charles River CEO Jim Foster might beg to differ. He's shown that being CEO comes with trauma. 
Via Investor's Business Daily
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.